Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma:A systematic review and meta-analysis of individual patient data
| Autor: | Paul A. Cohen, Aime Powell, Steffen Böhm, C. Blake Gilks, Colin J.R. Stewart, Tarek M. Meniawy, Max Bulsara, Stefanie Avril, Eleanor C. Brockbank, Tjalling Bosse, Gustavo Rubino de Azevedo Focchi, Raji Ganesan, Rosalind M. Glasspool, Brooke E. Howitt, Hyun-Soo Kim, Jung-Yun Lee, Nhu D. Le, Michelle Lockley, Ranjit Manchanda, Trupti Mandalia, W. Glenn McCluggage, Iain McNeish, Divya Midha, Radhika Srinivasan, Yun Yi Tan, Rachael van der Griend, Mayu Yunokawa, Gian F. Zannoni, Naveena Singh, Simi Aggarwal, Holger Bronger, Elizabeth B. Brown, Martin Buck, Syed A. Bukhari, Edwina Coghlan, Nichola Cope, Michelle Samora de Almeida, Cornelius D. De Kroon, Andrew Dean, Michael-John Devlin, Helena M. Ditzel, Enken Drecoll, Takahiro Ebata, Anna Fagotti, Asma Faruqi, Laura Feeney, Kavita Gupta, Ian Harley, Frediano Inzani, Arjun R. Jeyarajah, M.H. Eleanor Koay, Judith R. Kroep, Yee Leung, Alice R. Loft, Daniel MaGee, Sarah McKenna, David Millan, Joanne Millar, Rowan Miller, Ganendra R. Mohan, Sohail Mughal, Asima Mukhopadhyay, Sergio Mancini Nicolau, James Nevin, Abigail S. Oakley, Mary Quigley, Bhavana Rai, Arvind Rajwanshi, Stuart G. Salfinger, Giovanni Scambia, Kate Scatchard, Barbara Schmalfeldt, Bryony Simcock, Priya Singh, Kyle C. Strickland, Vainta Suri, Sheeba Syed, Peter Sykes, Kenji Tamura, Adeline Tan, Jason Tan, Emily Thompson, Anna V. Tinker, Georgia Trevisan, Maria Gabriela Baumgarten Kuster Uyeda, Michelle M. Vaughan, Wilko Weichert, Anthony Williams, Sarah Williams, Hiroshi Yoshida, Pier Carlo Zorzato |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Serous carcinoma IMPACT medicine.medical_treatment Chemotherapy response score High-grade serous tubo-ovarian cancer Neoadjuvant chemotherapy Prognosis Antineoplastic Agents Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Carboplatin Disease-Free Survival Fallopian Tube Neoplasms Female Humans Neoadjuvant Therapy Neoplasms Cystic Mucinous and Serous Ovarian Neoplasms Treatment Outcome chemistry.chemical_compound 0302 clinical medicine Carboplatin/therapeutic use Fallopian Tube Neoplasms/drug therapy Neoplasms Mucinous PRIMARY SURGERY Neoadjuvant therapy education.field_of_study Tumor TUMOR-REGRESSION Hazard ratio ADVANCED OVARIAN Obstetrics and Gynecology Obstetrics & Gynecology Ovarian Neoplasms/drug therapy CANCER ddc 030220 oncology & carcinogenesis Meta-analysis SURVIVAL Life Sciences & Biomedicine medicine.medical_specialty Population VALIDATION Biomarkers Tumor/analysis 03 medical and health sciences Cystic Internal medicine medicine Stage IIIC 1112 Oncology and Carcinogenesis Oncology & Carcinogenesis education Science & Technology business.industry and Serous Odds ratio medicine.disease HGSC CRS Collaborative Network (Supplementary 1) 030104 developmental biology Settore MED/40 - GINECOLOGIA E OSTETRICIA chemistry Neoplasms Cystic Mucinous and Serous/drug therapy 1114 Paediatrics and Reproductive Medicine Antineoplastic Combined Chemotherapy Protocols/therapeutic use business Biomarkers |
| Zdroj: | Cohen, P A, Powell, A, Böhm, S, Gilks, C B, Stewart, C J R, Meniawy, T M, Bulsara, M, Avril, S, Brockbank, E C, Bosse, T, de Azevedo Focchi, G R, Ganesan, R, Glasspool, R M, Howitt, B E, Kim, H S, Lee, J Y, Le, N D, Lockley, M, Manchanda, R, Mandalia, T, McCluggage, W G, McNeish, I, Midha, D, Srinivasan, R, Tan, Y Y, van der Griend, R, Yunokawa, M, Zannoni, G F, The HGSC CRS Collaborative Network (Supplementary 1) & Møgelbjerg Ditzel, H 2019, ' Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma : A systematic review and meta-analysis of individual patient data ', Gynecologic Oncology, vol. 154, no. 2, pp. 441-448 . https://doi.org/10.1016/j.ygyno.2019.04.679 Gynecologic Oncology, 154(2), 441-448. ACADEMIC PRESS INC ELSEVIER SCIENCE |
| DOI: | 10.1016/j.ygyno.2019.04.679 |
| Popis: | Objective. There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT.Methods. We established an international collaboration to conduct a systematic review and meta-analysis, pooling individual patient data from 16 sites in 11 countries. Patients had stage IIIC/IV HGSC, 3-4 NACT cycles and >6-months follow-up. Random effects models were used to derive combined odds ratios in the pooled population to investigate associations between CRS and progression free and overall survival (PFS and OS).Results. 877 patients were included from published and unpublished studies. Median PFS and OS were 15 months (IQR 5-65) and 28 months (IQR 7-92) respectively. CRS3 was seen in 249 patients (28%). The pooled hazard ratios (HR) for PFS and OS for CRS3 versus CRS1/CRS2 were 0.55 (95% CI, 0.45-0.66; P < 0.001) and 0.65 (95% CI 0.50-0.85, P = 0.002) respectively; no heterogeneity was identified (PFS: Q = 6.42, P = 0.698, I2 = 0.0%; OS: Q = 6.89, P = 0 648, I2 = 0.0%). CRS was significantly associated with PFS and OS in multivariate models adjusting for age and stage. Of 306 patients with known germline BRCA1/2 status, those with BRCA1/2 mutations (n = 80) were more likely to achieve CRS3 (P = 0.027).Conclusions. CRS3 was significantly associated with improved PFS and OS compared to CRS1/2. This validation of CRS in a real-world setting demonstrates it to be a robust and reproducible biomarker with potential to be incorporated into therapeutic decision-making and clinical trial design. (C) 2019 The Authors. Published by Elsevier Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|